Literature DB >> 31392498

Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study.

Nuh Atas1, Berkan Armagan2, Erdal Bodakci3, Hasan Satis4, Alper Sari2, Nazife Sule Yasar Bilge3, Reyhan Bilici Salman4, Gozde Kubra Yardımcı2, Hakan Babaoglu4, Aslihan Avanoglu Guler4, Hazan Karadeniz4, Levent Kilic2, Mehmet Akif Ozturk4, Berna Goker4, Seminur Haznedaroglu4, Umut Kalyoncu2, Timucin Kasifoglu3, Abdurrahman Tufan4.   

Abstract

Familial Mediterranean fever (FMF) is characterized by recurrent short-lived/self-limiting inflammatory attacks. Besides these, a substantial number of patients with FMF present with a variety of other inflammatory diseases; however, this issue has not been systematically studied previously. Hence, we aimed to investigate the frequency of inflammatory comorbid diseases in a large FMF cohort. All patients were recruited from "FMF in Central Anatolia (FiCA) Cohort", comprising 971 (mean age 35.3 ± 12 years, 61.5% female) adult subjects. All patients fulfilled Tel Hashomer criteria. Demographic data, FMF disease characteristics, MEFV gene mutations, and comorbid inflammatory diseases were meticulously questioned, and laboratory features and genotype data were retrieved from hospital records. There were comorbid inflammatory diseases in 205 (21.1%) patients. The most common inflammatory disease was spondyloarthritis (12.9%). Other remarkable inflammatory disorders were psoriasis, immunoglobulin A vasculitis/Henoch-Schönlein purpura, Behçet's disease and inflammatory bowel diseases. Cryptogenic organizing pneumonia is a newly defined entity in our cohort which is seemed to be associated with FMF (0.3%). Number of patients with persistent inflammation was higher in those with comorbid diseases (p < 0.001). Our results suggest that FMF is commonly associated with other inflammatory diseases. Therefore, clinicians should be cautious about comorbid inflammatory diseases in FMF patients, particularly in those with persistent inflammation. Identification of pathogenic pathways linking FMF to these diseases warrants further investigations.

Entities:  

Keywords:  Comorbidity; Familial Mediterranean fever; Inflammation; Interleukin-1 β; Spondyloarthritis

Year:  2019        PMID: 31392498     DOI: 10.1007/s00296-019-04412-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  48 in total

1.  Familial mediterranean fever and Behçet's disease--are they associated?

Authors:  Eldad Ben-Chetrit; Ronit Cohen; Tova Chajek-Shaul
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

Review 2.  Sensors of the innate immune system: their link to rheumatic diseases.

Authors:  Argyrios N Theofilopoulos; Rosana Gonzalez-Quintial; Brian R Lawson; Yi T Koh; Michael E Stern; Dwight H Kono; Bruce Beutler; Roberto Baccala
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

Review 3.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

4.  The activity of caspase-1 is increased in lesional psoriatic epidermis.

Authors:  Claus Johansen; Kristine Moeller; Knud Kragballe; Lars Iversen
Journal:  J Invest Dermatol       Date:  2007-06-28       Impact factor: 8.551

5.  The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.

Authors:  Ivona Aksentijevich; Christopher D Putnam; Hal M Hoffman; Daniel L Kastner; Elaine F Remmers; James L Mueller; Julie Le; Richard D Kolodner; Zachary Moak; Michael Chuang; Frances Austin; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheum       Date:  2007-04

6.  Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants.

Authors:  Je-Wook Yu; Teresa Fernandes-Alnemri; Pinaki Datta; Jianghong Wu; Christine Juliana; Leobaldo Solorzano; Margaret McCormick; ZhiJia Zhang; Emad S Alnemri
Journal:  Mol Cell       Date:  2007-10-26       Impact factor: 17.970

Review 7.  Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory.

Authors:  Elena Generali; Tanima Bose; Carlo Selmi; J Willem Voncken; Jan G M C Damoiseaux
Journal:  Autoimmun Rev       Date:  2018-07-11       Impact factor: 9.754

Review 8.  The arthritis of familial Mediterranean fever.

Authors:  A Garcia-Gonzalez; M H Weisman
Journal:  Semin Arthritis Rheum       Date:  1992-12       Impact factor: 5.532

9.  Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF).

Authors:  Erkan Demirkaya; Cengizhan Acikel; Philip Hashkes; Marco Gattorno; Ahmet Gul; Huri Ozdogan; Turker Turker; Omer Karadag; Avi Livneh; Eldad Ben-Chetrit; Seza Ozen
Journal:  Ann Rheum Dis       Date:  2016-01-28       Impact factor: 19.103

10.  Familial Mediterranean fever-associated diseases in children.

Authors:  Z B Özçakar; N Çakar; N Uncu; B A Çelikel; F Yalçinkaya
Journal:  QJM       Date:  2017-05-01
View more
  12 in total

Review 1.  Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review.

Authors:  Hazan Karadeniz; Aslıhan Avanoğlu Güler; Nuh Atas; Hasan Satış; Reyhan Bilici Salman; Hakan Babaoglu; Abdurrahman Tufan
Journal:  Rheumatol Int       Date:  2019-12-07       Impact factor: 2.631

2.  Kidney disease in a child with familial Mediterranean fever: Answers.

Authors:  Hakan Kisaoglu; Ozge Baba; Sevdegul Aydin Mungan; Mukaddes Kalyoncu
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.714

3.  Bibliometric analysis of publication activity in the field of familial Mediterranean fever in 2010-2019: a Scopus-based study.

Authors:  Burhan Fatih Kocyigit; Ahmet Akyol
Journal:  Rheumatol Int       Date:  2021-09-09       Impact factor: 2.631

4.  Spondyloarthritis in familial Mediterranean fever: a cohort study.

Authors:  Sevtap Acer Kasman; Mehmet Tuncay Duruöz
Journal:  Rheumatol Int       Date:  2022-06-18       Impact factor: 3.580

5.  Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease?

Authors:  Bayram Farisogullari; Muserref Kasap Cuceoglu; Hakan Oral; Gozde Kubra Yardimci; Yelda Bilginer; Seza Ozen; Omer Karadag
Journal:  Intern Emerg Med       Date:  2022-03-26       Impact factor: 5.472

6.  Enthesitis may be one of the signs of severe disease in familial Mediterranean fever.

Authors:  Nesrin Sen; Mesut Yilmaz; Ridvan Mercan; Omur Volkan; Sibel Yilmaz-Oner; Ezgi Tukel; Mehmet Engin Tezcan
Journal:  Clin Rheumatol       Date:  2020-09-12       Impact factor: 2.980

7.  Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists.

Authors:  Erdem Suticen; Nuh Atas; Aslihan Avanoglu Guler; Orhun Akdogan; Hakan Babaoğlu; Hasan Satis; Hazan Karadeniz; Seminur Haznedaroglu; Mehmet Akif Ozturk; Abdurrahman Tufan
Journal:  Clin Rheumatol       Date:  2021-02-01       Impact factor: 2.980

Review 8.  The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.

Authors:  Eitan Giat; Ilan Ben-Zvi; Merav Lidar; Avi Livneh
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

9.  Prediction of More Severe MEFV Gene Mutations in Childhood.

Authors:  Seviye Güneş-Yılmaz; Belde Kasap-Demir; Eren Soyaltın; Gökçen Erfidan; Özgür Özdemir-Şimşek; Seçil Arslansoyu-Çamlar; Demet Alaygut; Fatma Mutlubaş
Journal:  Turk Arch Pediatr       Date:  2021-11

10.  Phenotypic characterization of Familial Mediterranean Fever patients harboring variants of uncertain significance

Authors:  Alper Sarı; Erdal Bodakçi; Berkan Armağan; Hasan Satış; Nuh Ataş; Nazife Şule Yaşar Bilge; Reyhan Bilici Salman; Gözde Kübra Yardımcı; Hakan Babaoğlu; Levent Kılıç; Mehmet Akif Öztürk; Şeminur Haznedaroğlu; Berna Göker; Umut Kalyoncu; Timuçin Kaşifoğlu; Abdurrahman Tufan
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.